Last reviewed · How we verify
"Nefecon®","Ambrisentan"
Ambrisentan selectively blocks endothelin-1 receptors on vascular endothelial cells, reducing vasoconstriction and pulmonary vascular remodeling.
Ambrisentan selectively blocks endothelin-1 receptors on vascular endothelial cells, reducing vasoconstriction and pulmonary vascular remodeling. Used for Pulmonary arterial hypertension (PAH).
At a glance
| Generic name | "Nefecon®","Ambrisentan" |
|---|---|
| Sponsor | The First Hospital of Jilin University |
| Drug class | Endothelin receptor antagonist (ERA) |
| Target | Endothelin receptor type A (ETA) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ambrisentan is an endothelin receptor antagonist (ERA) that preferentially binds to endothelin type-A (ETA) receptors. By blocking ETA receptors, it prevents endothelin-1-mediated vasoconstriction and smooth muscle proliferation in pulmonary blood vessels, thereby reducing pulmonary vascular resistance and improving hemodynamics in pulmonary arterial hypertension.
Approved indications
- Pulmonary arterial hypertension (PAH)
Common side effects
- Peripheral edema
- Headache
- Nasal congestion
- Palpitations
- Liver enzyme elevation
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- "Nefecon®","Ambrisentan" CI brief — competitive landscape report
- "Nefecon®","Ambrisentan" updates RSS · CI watch RSS
- The First Hospital of Jilin University portfolio CI